In contrast to breast cancer, where HER2 amplification, but not chromosome 17 polysomy seems to confer sensitivity to monoclonal antibody trastuzumab [34,35], it has been reported that patients with NSCLC can derive a clinical benefit from TKIs therapy when EGFR increased copy number (ICN) is found, without distinction between amplification and/or high level of chromosome 7p polisomy. Here, ERBB2 is linked to breast cancer.